Phase of Development: In Vivo Proof of Concept

Mechanism of Action: Neuroinflammation

Compound Type/Modality: Small Molecule

Targeting CNS LDLR to ameliorate tau-mediated neurodegeneration

David Holtzman, MD

Washington University (St. Louis, MO)
Andrew B. & Gretchen P. Jones Professor of Neurology and Developmental Biology

For further information about this program Contact: